Glioblastoma multiforme (GBM) is a WHO grade IV glioma and the most common malignant,
primary brain tumor with a 5-year survival of 7.2%. Its highly infiltrative nature, genetic …

Emerging ultrasonic bioelectronics (UBEs) with wearable, implantable or highly integrated
forms enable continuous health monitoring and on-demand medical therapy at the point of …

Amplification of chromosome 7p11 (7p11) is the most common alteration in primary
glioblastoma (GBM), resulting in gains of epidermal growth factor receptor (EGFR) copy …

Immunogenic cell death (ICD) is a regulated cell death (RCD) pathway. In response to
physical and chemical signals, tumor cells activate specific signaling pathways that stimulate …

Background High-grade gliomas are primary brain cancers with unacceptably low and
persistent survival rates of 10–16 months for WHO grade 4 gliomas over the last 40 years …

Glioblastoma multiforme (GBM) is an aggressive brain tumor with high mortality rates. Due to
its invasiveness, heterogeneity, and incomplete resection, the treatment is very challenging …

Glioblastoma (GB) stands out as the most prevalent and lethal form of brain cancer.
Although great efforts have been made by clinicians and researchers, no significant …

Alzheimer's disease is one of the most common neurodegenerative conditions, which are
ascribed to extracellular accumulation of β-amyloid peptides into plaques. This …

Glioblastoma (GBM) is an aggressive malignancy of the central nervous system (CNS) that
remains incurable despite the multitude of improvements in cancer therapeutics. The …

Simple Summary There is a pressing need for new effective treatments against glioma. A
promising option is a class of drugs called poly (ADP-Ribose) polymerase (PARP) inhibitors …